This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Limited Sampling Strategy and Target Attainment Analysis for Levofloxacin in Patients 1
with Tuberculosis 2
Abdullah Alsultan,1 Guohua An,2 Charles A. Peloquin1 3
1University of Florida, College of Pharmacy, Department of Pharmacotherapy and 4
Translational Research, Gainesville, FL, 2University of Iowa, Department of 5
Pharmaceutical Sciences and Experimental Therapeutics, Iowa City, Iowa 6
Keywords: Levofloxacin, tuberculosis, limited sampling strategy, therapeutic drug 7
monitoring, simulation, target attainment 8
Running Title: Levofloxacin PK and limited sampling strategy 9
Part of this work was presented at the 54th Interscience Conference on Antimicrobial Agents and 335
Chemotherapy, Washington, DC, September, 2014 336
337
References 338
1. Anonymous. 1986. Long-term follow-up of a clinical trial of six-month and four-month regimens 339 of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis 340 Service/British Medical Research Council. Am Rev Respir Dis 133:779-783. 341
2. Anonymous. 1981. Clinical trial of six-month and four-month regimens of chemotherapy in the 342 treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 62:95-102. 343
3. Ji B, Lounis N, Truffot-Pernot C, Grosset J. 1995. In vitro and in vivo activities of levofloxacin 344 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:1341-1344. 345
4. Perlman DC, El Sadr WM, Heifets LB, Nelson ET, Matts JP, Chirgwin K, Salomon N, Telzak EE, 346 Klein O, Kreiswirth BN, Musser JM, Hafner R. 1997. Susceptibility to levofloxacin of 347 Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and 348 characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical 349 Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. Aids 11:1473-1478. 350
5. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. 2003. Comparative roles of 351 levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary 352 results of a retrospective study from Hong Kong. Chest 124:1476-1481. 353
6. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to 354 bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother 37:1287-1298. 355
7. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to 356 bacterial killing rates. Part 2: human trials. Ann Pharmacother 37:1478-1488. 357
8. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, 358 Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin 359 against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that 360 best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. 361
9. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. 2004. Selection of a 362 moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an 363 in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 190:1642-364 1651. 365
10. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics 366 of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-367 1081. 368
11. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow response 369 to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16:1546-370 1553. 371
12. Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. 2013. Early Therapeutic Drug Monitoring for 372 Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. 373 Tuberc Res Treat 2013:129723. 374
13. Alsultan A, Peloquin CA. 2014. Therapeutic drug monitoring in the treatment of tuberculosis: an 375 update. Drugs 74:839-854. 376
14. Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. 2013. Therapeutic drug 377 monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis 378 17:221-224. 379
15. Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R. 2012. Therapeutic 380 drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 25:83-86. 381
16. Babalik A, Mannix S, Francis D, Menzies D. 2011. Therapeutic drug monitoring in the treatment 382 of active tuberculosis. Can Respir J 18:225-229. 383
17. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum Drug 384 Concentrations Predictive of Pulmonary Tuberculosis Outcomes. J Infect Dis. 385
18. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, 386 Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide 387 pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of 388 adults with tuberculosis from Botswana. Clin Infect Dis 48:1685-1694. 389
19. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao 390 Z, Hodge T. 2005. Association between acquired rifamycin resistance and the pharmacokinetics 391 of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40:1481-392 1491. 393
20. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van 394 Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma concentrations in 395 relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob 396 Agents Chemother 57:3614-3619. 397
21. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population 398 pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary 399 tuberculosis. Antimicrob Agents Chemother 52:852-857. 400
22. Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree 401 MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE. 2014. Population 402 pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and 403 moxifloxacin. Int J Antimicrob Agents 44:229-234. 404
23. Sprague DA, Ensom MH. 2009. Limited-sampling strategies for anti-infective agents: systematic 405 review. Can J Hosp Pharm 62:392-401. 406
24. Lavielle M, Mentre F. 2007. Estimation of population pharmacokinetic parameters of saquinavir 407 in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34:229-249. 408
25. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, 409 Peloquin CA. 2002. Population pharmacokinetic modeling of pyrazinamide in children and adults 410 with tuberculosis. Pharmacotherapy 22:686-695. 411
26. Alsultan A, Dooley K, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin C. 2013. Population 412 Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis, abstr American Conference on 413 Pharmacometrics, 414
27. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J 415 Pharmacokinet Biopharm 9:503-512. 416
28. Anonymous. R Core Team (2014). R: A language and environment for statistical computing. R 417 Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. 418
29. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, 419 Bharath S, Kantharaj E, Balasubramanian V. 2004. Isoniazid pharmacokinetics-420 pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 421 48:2951-2957. 422
30. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil 423 RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in 424 an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47:2118-2124. 425
31. Akkerman OW, van Altena R, Bolhuis MS, van der Werf TS, Alffenaar JW. 2014. Strategy to 426 limit sampling of antituberculosis drugs instead of determining concentrations at two hours 427 postingestion in relation to treatment response, p 628, Antimicrob Agents Chemother, vol 58, 428 United States. 429
32. Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar 430 JW. 2011. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in 431 patients with tuberculosis. Ther Drug Monit 33:350-354. 432
33. Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. 2010. Limited 433 sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-434 resistant tuberculosis. Ther Drug Monit 32:97-101. 435
34. Tanigawara Y, Nomura H, Kagimoto N, Okumura K, Hori R. 1995. Premarketing population 436 pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. 437 Biol Pharm Bull 18:315-320. 438
35. Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang 439 YY. 2009. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in 440 community-acquired lower respiratory tract infections: results of a prospective multicenter 441 study in China. J Infect Chemother 15:293-300. 442
36. Ginsburg AS, Woolwine SC, Hooper N, Benjamin WH, Jr., Bishai WR, Dorman SE, Sterling TR. 443 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis, p 1977-1978, N 444 Engl J Med, vol 349, United States. 445
38. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, 448 Drusano GL. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence 449 of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 195:1818-1827. 450
39. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, 451 Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, Group PT. 2003. Comparison of 8 vs 15 days of 452 antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 453 290:2588-2598. 454
40. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. 2000. Short-course empiric antibiotic 455 therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution 456 for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162:505-511. 457
41. D'Agata EM, Magal P, Olivier D, Ruan S, Webb GF. 2007. Modeling antibiotic resistance in 458 hospitals: the impact of minimizing treatment duration. J Theor Biol 249:487-499. 459
42. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. 2011. Effect of administration 460 of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 461 days in an in vitro pharmacodynamic system. MBio 2:e00108-00111. 462
43. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, 463 Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik 464 T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, 465 Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, 466 Akksilp S, Investigators GPETTSP. 2014. Extensive drug resistance acquired during treatment of 467 multidrug-resistant tuberculosis. Clin Infect Dis 59:1049-1063. 468
44. Alffenaar JW, Gumbo T, Aarnoutse RE. 2015. Acquired drug resistance: we can do more than 469 we think! Clin Infect Dis 60:969-970. 470